ANRIL, H19 and TUG1: a review about critical long non-coding RNAs in cardiovascular diseases

Lívia da Cunha Agostini1, Tamires Cunha Almeida2, Glenda Nicioli da Silva3,4

  • 1Programa de Pós-Graduação em Ciências Farmacêuticas (CiPharma), Escola de Farmácia, Universidade Federal de Ouro Preto, Morro do Cruzeiro, s/nº, Ouro Prêto, Minas Gerais, CEP 35402-163, Brazil.

Molecular Biology Reports
|December 28, 2023
PubMed

Insights

Long non-coding RNAs (lncRNAs) show promise in diagnosing and preventing cardiovascular diseases. Understanding lncRNA mechanisms like ANRIL, H19, and TUG1 aids early detection and intervention for conditions like heart failure and stroke.

Area of Science:

  • Cardiovascular Science
  • Molecular Biology
  • Genetics

Background:

  • Cardiovascular diseases (CVDs) are the primary global cause of mortality.
  • Risk factors include smoking, diabetes, and genetic predisposition.
  • Long non-coding RNAs (lncRNAs) are increasingly linked to CVD development.

Purpose of the Study:

  • To review recent discoveries on lncRNA mechanisms in cardiovascular pathologies.
  • To highlight the clinical relevance of specific lncRNAs (ANRIL, H19, TUG1).
  • To explore lncRNAs as potential biomarkers for early CVD detection.

Main Methods:

  • Literature review of recent research on lncRNAs and cardiovascular diseases.
  • Analysis of studies focusing on ANRIL, H19, and TUG1.
  • Synthesis of findings on lncRNA function and clinical implications.

Main Results:

  • lncRNAs are implicated in the susceptibility to hypertension, myocardial infarction, stroke, and heart failure.
  • Specific lncRNAs (ANRIL, H19, TUG1) play crucial roles in cardiovascular disease mechanisms.
  • lncRNAs offer potential for novel diagnostic and preventive strategies.

Conclusions:

  • lncRNAs represent a promising avenue for the prevention and diagnosis of cardiovascular diseases.
  • Further research into lncRNA mechanisms can facilitate early detection and intervention.
  • Targeting lncRNAs may help prevent the establishment of cardiovascular pathological phenotypes.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
94
Regulation of the Cardiovascular System01:27

Regulation of the Cardiovascular System

The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
1.1K
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
160
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K